Araştırma Makalesi

Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma

Cilt: 49 Sayı: 1 5 Mart 2018
PDF İndir
TR EN

Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma

Öz

Objective: Endometrial carcinomas are divided into two groups roughly:Endometrioid (Type I) and Non-endometrioid (Type II). The majority of the endometrial carcinomas are of endometrioid type and, this type of carcinoma is associated with hyperplasia which is formed due to unopposed estrogen.In this study, our purpose is to reveal the expression status of the PTEN, MLH1, ARID1A and β-catenin, biomarkers in all types of endometrial hyperplasia (EH) and endometrioid endometrial carcinoma (EC).

Materials and metods: We conducted a retrospective study with 202 cases including 82 EC cases, 71 simple EH cases without atypia, 16 complex EH cases without atypia, 9 simple atypical EH cases, 24 complex atypical EH cases which were diagnosed at Istanbul Civilization University Göztepe Training and Research Hospital. 10 normal endometrial tissues were used for the purpose of control.

Resuls: In our study, loss of PTEN ratio was 61%, loss of ARID1A ratio was 52,4%, loss of MLH1 ratio was 40,2% in patients with EC. These ratios were 87,5%, 41,7%, 20,8%, respectively in patients with atypical complex EH and 12,7%; 4,2%; 1,4% in patients with simple EH without atypia.

Conclusions: In the light of these findings it has been demonstrated that PTEN, ARID1A and MLH1 have a role in the transition from simple EH to atypical complex EH, and also MLH1 has a role in the transition from aytpical complex EH to EC. 

Anahtar Kelimeler

Kaynakça

  1. Sherman ME et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. ModPathol (1997) 10:963-968.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Duygu Kösemetin Döver * Bu kişi benim
Türkiye

Abdullah Aydın Bu kişi benim
Türkiye

Serkan Senol Bu kişi benim
Türkiye

Yayımlanma Tarihi

5 Mart 2018

Gönderilme Tarihi

16 Aralık 2017

Kabul Tarihi

13 Şubat 2018

Yayımlandığı Sayı

Yıl 2018 Cilt: 49 Sayı: 1

Kaynak Göster

APA
Kösemetin Döver, D., Aydın, A., Senol, S., Bostancı, E., & Kılıccı, C. (2018). Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma. Zeynep Kamil Tıp Bülteni, 49(1), 65-71. https://doi.org/10.16948/zktipb.367326
AMA
1.Kösemetin Döver D, Aydın A, Senol S, Bostancı E, Kılıccı C. Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma. Zeynep Kamil Tıp Bülteni. 2018;49(1):65-71. doi:10.16948/zktipb.367326
Chicago
Kösemetin Döver, Duygu, Abdullah Aydın, Serkan Senol, Evrim Bostancı, ve Cetin Kılıccı. 2018. “Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma”. Zeynep Kamil Tıp Bülteni 49 (1): 65-71. https://doi.org/10.16948/zktipb.367326.
EndNote
Kösemetin Döver D, Aydın A, Senol S, Bostancı E, Kılıccı C (01 Mart 2018) Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma. Zeynep Kamil Tıp Bülteni 49 1 65–71.
IEEE
[1]D. Kösemetin Döver, A. Aydın, S. Senol, E. Bostancı, ve C. Kılıccı, “Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma”, Zeynep Kamil Tıp Bülteni, c. 49, sy 1, ss. 65–71, Mar. 2018, doi: 10.16948/zktipb.367326.
ISNAD
Kösemetin Döver, Duygu - Aydın, Abdullah - Senol, Serkan - Bostancı, Evrim - Kılıccı, Cetin. “Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma”. Zeynep Kamil Tıp Bülteni 49/1 (01 Mart 2018): 65-71. https://doi.org/10.16948/zktipb.367326.
JAMA
1.Kösemetin Döver D, Aydın A, Senol S, Bostancı E, Kılıccı C. Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma. Zeynep Kamil Tıp Bülteni. 2018;49:65–71.
MLA
Kösemetin Döver, Duygu, vd. “Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma”. Zeynep Kamil Tıp Bülteni, c. 49, sy 1, Mart 2018, ss. 65-71, doi:10.16948/zktipb.367326.
Vancouver
1.Duygu Kösemetin Döver, Abdullah Aydın, Serkan Senol, Evrim Bostancı, Cetin Kılıccı. Utility of PTEN, MLH1, ARID1A and β-catenin, biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma. Zeynep Kamil Tıp Bülteni. 01 Mart 2018;49(1):65-71. doi:10.16948/zktipb.367326